How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?
出版年份 2020 全文链接
标题
How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?
作者
关键词
-
出版物
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
Volume 40, Issue 3, Pages 506-522
出版商
Ovid Technologies (Wolters Kluwer Health)
发表日期
2020-01-30
DOI
10.1161/atvbaha.119.311904
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus
- (2019) Thea Anine Strøm Halden et al. DIABETES CARE
- Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042–2050
- (2019) Lennart Tonneijck et al. DIABETES CARE
- Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomised controlled study
- (2019) Zeeshan Javed et al. CLINICAL ENDOCRINOLOGY
- Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of MajorAdverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
- (2019) Thomas A. Zelniker et al. CIRCULATION
- Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial
- (2019) Maurice B. Bizino et al. Cardiovascular Diabetology
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide treatment reduced interleukin 6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy
- (2019) C. Brock et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients
- (2019) Huub J. van Eyk et al. Cardiovascular Diabetology
- Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial
- (2019) Subodh Verma et al. CIRCULATION
- Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial
- (2019) Michael E. Nassif et al. CIRCULATION
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial
- (2019) Erik J.M. van Bommel et al. KIDNEY INTERNATIONAL
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2019) Søren L Kristensen et al. Lancet Diabetes & Endocrinology
- Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes
- (2018) Vaia Lambadiari et al. Cardiovascular Diabetology
- Effects of liraglutide on gallbladder emptying: A randomized, placebo-controlled trial in adults with overweight or obesity
- (2018) Christina C. Nexøe-Larsen et al. DIABETES OBESITY & METABOLISM
- Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
- (2018) Jan W. Eriksson et al. DIABETOLOGIA
- Effects of liraglutide, metformin, and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: a randomized trial
- (2018) Wen-Huan Feng et al. Journal of Diabetes Investigation
- Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS
- (2018) Signe Frøssing et al. Endocrine Connections
- One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients
- (2018) C. K. Svensson et al. ACTA PSYCHIATRICA SCANDINAVICA
- Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus
- (2018) Mojca Lunder et al. Cardiovascular Diabetology
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETES CARE
- Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes
- (2018) Kenneth Cusi et al. DIABETES OBESITY & METABOLISM
- Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETOLOGIA
- Liraglutide, sitagliptin and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and NAFLD
- (2018) Jinhua Yan et al. HEPATOLOGY
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
- (2017) Dilan Athauda et al. LANCET
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide causes large and rapid epicardial fat reduction
- (2017) Gianluca Iacobellis et al. Obesity
- Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial
- (2017) Malin Nylander et al. REPRODUCTIVE BIOMEDICINE ONLINE
- SU18. GLP-1 Receptor Agonist Treatment in Schizophrenia Patients With Obesity
- (2017) Pelle L. Ishøy et al. SCHIZOPHRENIA BULLETIN
- Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease
- (2017) Wenhuan Feng et al. Journal of Diabetes
- Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment vs. Glimepiride Both in Combination with Metformin: A Randomized Open Parallel-Group Study
- (2017) Thomas Nyström et al. Frontiers in Endocrinology
- Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study
- (2016) Preman Kumarathurai et al. Cardiovascular Diabetology
- Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac ArrestClinical Perspective
- (2016) Sebastian Wiberg et al. CIRCULATION
- Effects of Liraglutide on Reperfusion Injury in Patients With ST-Segment–Elevation Myocardial InfarctionCLINICAL PERSPECTIVE
- (2016) Wei Ren Chen et al. Circulation-Cardiovascular Imaging
- Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients
- (2016) Mark M. Smits et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes
- (2016) Per Lundkvist et al. DIABETES OBESITY & METABOLISM
- Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial
- (2016) Mark M. Smits et al. DIABETOLOGIA
- Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial
- (2016) Mark M Smits et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial
- (2016) Anders Jorsal et al. EUROPEAN JOURNAL OF HEART FAILURE
- No benefit of additional treatment with exenatide in patients with an acute myocardial infarction
- (2016) Sebastiaan T. Roos et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
- (2016) A Blackman et al. INTERNATIONAL JOURNAL OF OBESITY
- Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction
- (2016) Kenneth B. Margulies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study
- (2015) Mamta Jaiswal et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide – A pilot study
- (2015) Sarah Anne Robert et al. Obesity Research & Clinical Practice
- The effect of liraglutide on endothelial function in patients with type 2 diabetes
- (2014) Debashis Nandy et al. Diabetes & Vascular Disease Research
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
- (2014) Kathleen M Dungan et al. LANCET
- Cardioprotective Effects of Exenatide in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
- (2013) Jong Shin Woo et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Exenatide and the treatment of patients with Parkinson’s disease
- (2013) Iciar Aviles-Olmos et al. JOURNAL OF CLINICAL INVESTIGATION
- Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: a randomized trial
- (2012) Aaron S Kelly et al. Cardiovascular Diabetology
- Exenatide Reduces Final Infarct Size in Patients With ST-Segment–Elevation Myocardial Infarction and Short-Duration of Ischemia
- (2012) Jacob Lønborg et al. Circulation-Cardiovascular Interventions
- Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function
- (2012) T. Forst et al. DIABETIC MEDICINE
- Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study
- (2010) Anne Gill et al. Cardiovascular Diabetology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now